EGF Theramed Health (TMED) AI Stock Analysis

• Market Cap: C$929.33K
• Dividend Yield: N/A
• Average Volume (3M): 1.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: N/A
• EPS Growth: -1188.37%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 11,616,665
• 10 Day Avg. Volume: 1,800
• 30 Day Avg. Volume: 1,233
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 38.98
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: C$0.08 ▲(7.14% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is driven down primarily by very weak financial performance (no revenue, ongoing losses, negative equity and a thin asset base), compounded by strongly bearish technical momentum (below key moving averages with negative MACD and extremely low RSI). Valuation offers limited support because earnings are negative and no dividend yield is available.

Positive Factors

Positive operating/free cash flow in 2025

A shift to positive operating and free cash flow, even modest, indicates management moves toward cash discipline and reduced reliance on immediate external funding. Over 2-6 months this provides a less acute liquidity squeeze and a foundation to stabilize operations if sustained and scaled.

Negative Factors

No reported revenue across years

Zero reported revenue indicates an unproven commercial model and lack of product-market traction. Without revenue, the firm cannot demonstrate sustainable unit economics, forcing reliance on external capital and increasing long-term dilution and survival risk if commercialization stalls.

EGF Theramed Health Business Overview & Revenue Model

Company Description

EGF Theramed Health Corp. provides psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression. The company was incorporated in...

Read more

EGF Theramed Health Corp. provides psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression. The company was incorporated in...

How the Company Makes Money

null...

EGF Theramed Health Financial Statement Overview

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	―
EBITDA	-2.21M	-2.33M	-238.64K	-568.50K	-1.35M	-677.89K
Net Income	-3.09M	-3.21M	-269.25K	-623.00K	-1.69M	-968.71K
Balance Sheet
Total Assets	18.25K	22.34K	214.41K	193.69K	178.67K	1.20M
Cash, Cash Equivalents and Short-Term Investments	10.47K	14.01K	10.01K	11.72K	15.23K	702.63K
Total Debt	1.63M	1.51M	1.47M	1.34M	1.22M	1.12M
Total Liabilities	6.06M	5.93M	2.92M	2.67M	2.51M	2.41M
Stockholders Equity	-4.64M	-4.52M	-1.34M	-1.14M	-1.02M	91.48K
Cash Flow
Free Cash Flow	82.28K	29.75K	-134.71K	-576.01K	-993.42K	-783.76K
Operating Cash Flow	82.30K	29.75K	-134.71K	-576.01K	-993.42K	-783.76K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	410.43K
Financing Cash Flow	104.98K	-25.75K	133.00K	572.50K	306.02K	712.20K

EGF Theramed Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.07
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TMED, the sentiment is Positive. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 97.22 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TMED.

EGF Theramed Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NDAT	45 Neutral	C$3.72M	-4.56	-34.06%	―	-100.00%	65.85%
NARA	42 Neutral	C$6.67M	-4.68	―	―	―	81.01%
TMED	38 Underperform	C$929.33K	-2.71	78.43%	―	―	-1188.37%
KETA	38 Underperform	C$632.53K	-7.33	0.59%	―	―	―
DMED	―	C$13.14M	-21.40	527.45%	―	―	-67.11%

EGF Theramed Health Corporate Events